Amanta Healthcar

Should I buy, sell or hold Amanta Healthcare Ltd?

Why is Amanta Healthcare Ltd falling/rising?

As of 04-Aug, Amanta Healthcare Ltd's stock price is at 170.05, down 0.76% after a trend reversal following five days of gains. The decline is linked to decreased investor participation and underperformance relative to its sector, despite a strong year-to-date increase of 56.44%.

As of 04-Aug, Amanta Healthcare Ltd's stock price is currently at 170.05, reflecting a decrease of 1.3 points or 0.76%. This decline can be attributed to several factors. Firstly, the stock has recently experienced a trend reversal, falling after five consecutive days of gains, indicating a potential shift in market sentiment. Additionally, the stock has underperformed its sector by 0.71% today, suggesting that it is not keeping pace with its peers.<BR><BR>Investor participation has also decreased, as evidenced by a significant drop in delivery volume, which fell by 96.37% compared to the five-day average. This decline in trading activity may indicate waning interest among investors, contributing to the downward pressure on the stock price. <BR><BR>Despite these short-term challenges, it is worth noting that Amanta Healthcare Ltd has shown strong performance over longer periods, with a year-to-date increase of 56.44%, significantly outperforming the Sensex, which has decreased by 7.97% in the same timeframe. However, the current market dynamics suggest that the stock is facing immediate headwinds, leading to its recent price decline.

Which are the latest news on Amanta Healthcar?

When is the next results date for Amanta Healthcare Ltd?

The next results date for Amanta Healthcare Ltd is August 5, 2026.

The next results date for Amanta Healthcare Ltd is scheduled for August 5, 2026.

What does Amanta Healthcar do?

Amanta Healthcare Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 77 Cr and a net profit of 6 Cr for March 2026. The company, originally founded in 1994, has undergone several name changes and currently has a market cap of INR 537 Cr.

Overview:<BR>Amanta Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1994 as Marck Parenterals (India) Limited. It underwent several name changes, becoming Marck Biosciences Limited in 2005 and finally Amanta Healthcare Limited in 2014. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 77 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 6 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 537 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 33.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.69 <BR>Return on Equity: 7.60% <BR>Price to Book: 2.37 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Amanta Healthcar?

As of 10th June, Amanta Healthcare Ltd has a market capitalization of 537.00 Cr, with recent net sales of 287.68 Cr and a net profit of 14.88 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Amanta Healthcare Ltd has a market capitalization of 537.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 287.68 Cr, while the sum of Net Profit for the same period is 14.88 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 96.39 Cr, and Total Assets amount to 381.76 Cr.

Who are the peers of the Amanta Healthcar?

Amanta Healthcar's peers include Anuh Pharma, Shree Ganesh Rem, Kilitch Drugs, Zim Laboratories, Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, and Albert David. Management and growth risks vary among peers, with Bafna Pharma showing the highest 1-year return at 135.40%, while Anuh Pharma has the lowest at -28.01%.

Peers: The peers of Amanta Healthcar are Anuh Pharma, Shree Ganesh Rem, Kilitch Drugs, Zim Laboratories, Jenburkt Pharma, Bafna Pharma, Haleos Labs Limi, CCME Global, and Albert David.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kilitch Drugs, Jenburkt Pharma, and Albert David, while Average management risk is found at Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Haleos Labs Limi, and Amanta Healthcar. Below Average management risk is present at Bafna Pharma, CCME Global. Growth is Excellent at Kilitch Drugs, while Average growth is noted at Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, Haleos Labs Limi, and Albert David. Below Average growth is seen at Bafna Pharma and CCME Global. Capital Structure is Excellent at Anuh Pharma, Shree Ganesh Rem, and Jenburkt Pharma, Good at Kilitch Drugs, Bafna Pharma, and CCME Global, while Average is noted at Zim Laboratories, and Below Average at Amanta Healthcar and Haleos Labs Limi.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma at 135.40%, while the peer with the lowest is Anuh Pharma at -28.01%. Amanta Healthcar's 1-year return is not available for comparison. Additionally, Haleos Labs Limi, CCME Global, and Albert David have negative six-month returns.

Are Amanta Healthcare Ltd latest results good or bad?

Amanta Healthcare Ltd's latest results show a mixed performance, with a net profit increase of 19.44% and revenue growth of 6.84%, but a decline in operating margins and ongoing operational challenges suggest the results are not entirely favorable. The company needs to address these issues for sustainable growth and profitability.

Amanta Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹5.53 crores for Q4 FY26, which is a significant increase of 19.44% compared to the previous quarter. Additionally, revenue grew by 6.84% year-on-year, reaching ₹76.99 crores, marking the highest quarterly revenue in recent times.<BR><BR>However, there are notable concerns as well. The operating margin has declined to 19.42%, down from 20.62% in the previous quarter and significantly lower than 26.31% in the same quarter last year. This decline indicates potential challenges in pricing power or increased costs, which could affect profitability moving forward.<BR><BR>Moreover, while the company has shown some improvement in net profit, it remains below the previous year's figures, reflecting ongoing operational challenges. The average return on equity (ROE) of 8.18% and return on capital employed (ROCE) of 13.97% over the past five years suggest that the company is facing issues with capital efficiency and profitability.<BR><BR>In summary, while there are positive aspects such as revenue growth and improved net profit, the decline in margins and underlying operational challenges indicate that the results are not entirely favorable. The company is at a critical juncture, needing to address these issues to ensure sustainable growth and profitability.